Shares of Alimera Sciences and Geron Downgraded Recently
Wall St. Watchdog reveals information about companies for which stock analysts downgraded shares in the Healthcare sector for the week ending November 18th, 2011.
- Alimera Sciences (NASDAQ:ALIM): Rodman & Renshaw downgraded its rating on this company from Mkt Outperform to Mkt Perform on Nov 14th. The shares recently traded at $1.28, down $0.3, or 18.99% since the analyst’s rating. About the company: Alimera Sciences Inc. is a biopharmaceutical company. The Company researches, develops and commercializes prescription ophthalmic pharmaceuticals. Alimera Sciences is focused on diseases affecting the lining in the back of the eye, or retina. Get the most recent company news and stock data here >>
- Geron (NASDAQ:GERN): WBB Securities downgraded its rating on this company from Strong Buy to Speculative Buy and changed its price target from $19 to $6 on Nov 16th. The shares recently traded at $1.68, up $0.06, or 3.7% since the analyst’s rating. About the company: Geron Corporation, a biopharmaceutical company, discovers and develops therapeutic and diagnostic products to treat cancer and other age-related degenerative diseases including spinal cord injury, heart failure and diabetes. Get the most recent company news and stock data here >>
(Note: Selected financial data are sourced from Briefing.com via the Wall St. Journal. All data are assumed to be accurate.)
Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>